DIAGNOS Announces a New Strategic Partnership Agreement in Costa Rica
December 12 2019 - 8:00AM
Diagnos Inc. (“DIAGNOS”, “the Corporation” or ”We”) (TSX Venture:
ADK) (OTCQB: DGNOF) a leader in early detection of critical health
issues through the use of its FLAIRE platform based on Artificial
Intelligence (AI), announces today a new partnership agreement with
a local firm (the “Partner”) to market DIAGNOS’ AI solutions in
Costa Rica.
“After careful consideration, due to its edge
technology, unique AI solution, testimonial and scientific
evidence, we have concluded that DIAGNOS is the right partner for
introducing an integrated screening solution to our local market.
There is a captive private health sector wanting the service and
the strategy is to show the benefits and signing substantial
contracts involving high volume of patients”, said the Partner. “We
just performed a successful health campaign and confirmed how
outstanding DIAGNOS’ AI platform is. I’m sure we will have a
positive impact on thousands of lives”, also said the Partner.
“DIAGNOS continues its effort to make its
real-time eye screening AI platform accessible. We estimate having
positively impacted more than 155,000 lives in Latin America, by
preserving their vision. We strongly believe, due to our Partner’s
experience in the health IT field for the last 20 years, that this
new collaboration will lead us to important projects in order to
benefit more and more people. The references from our results in
Mexico, and other countries, support the positive evidence of our
high-tech solution in the avoidance of blindness caused by
diabetes. In addition to saving substantial costs to the public
health budgets, we also generate positive experiences to patients”,
said Guillermo Moreno, Vice President at DIAGNOS.
About DIAGNOSDIAGNOS is a publicly-traded
Canadian corporation with a mission of early detection of critical
health issues through the use of its Artificial Intelligence (“AI”)
tool CARA (Computer Assisted Retina Analysis). CARA is a
tele-ophthalmology platform that integrates with existing equipment
(hardware and software) and processes at the point of care. CARA’s
Artificial Intelligence image enhancement algorithms make standard
retinal images sharper, clearer and easier to read. CARA is
accessible securely over the internet, and is compatible with all
recognized image formats and brands of fundus cameras, and is EMR
compatible. CARA is a cost-effective tool for screening large
numbers of patients in real-time. CARA complies with local
regulations, is FDA cleared for commercialization in the United
States of America is Health Canada licensed for commercialization
in Canada and is CE marking compliant in Europe.
Additional information is available at
www.diagnos.com and www.sedar.com
For further information, please contact:
Mr. André Larente, PresidentDIAGNOS Inc.Tel:
450-678-8882 ext. 224alarente@diagnos.ca
This news release contains forward-looking
information. There can be no assurance that forward-looking
information will prove to be accurate, as actual results and future
events could differ materially from those anticipated in these
statements. DIAGNOS disclaims any intention or obligation to
publically update or revise any forward-looking information,
whether as a result of new information, future events or otherwise.
The forward-looking information contained in this news release is
expressly qualified by this cautionary statement.
Neither the TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release.
Diagnos (TSXV:ADK)
Historical Stock Chart
From Mar 2024 to Apr 2024
Diagnos (TSXV:ADK)
Historical Stock Chart
From Apr 2023 to Apr 2024